Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE AND HYDROCHLOROTHIAZIDE versus NATURETIN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE AND HYDROCHLOROTHIAZIDE versus NATURETIN 10.
HYDRALAZINE AND HYDROCHLOROTHIAZIDE vs NATURETIN-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting smooth muscle vasodilator that relaxes arterioles, reducing peripheral resistance. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance and has antihypertensive effects.
Oral: 1 tablet (hydralazine 25 mg / hydrochlorothiazide 25 mg) 1-2 times daily. Maximum: hydralazine 200 mg/day, hydrochlorothiazide 50 mg/day.
Adults: 10 mg orally once daily.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); extended in renal impairment. Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal elimination half-life is approximately 2-4 hours; clinical context: dose adjustments may be needed in renal impairment.
Hydralazine: 80-90% renal (mostly as metabolites), <10% unchanged. Hydrochlorothiazide: 95-99% renal (unchanged).
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal elimination accounts for the remainder (30-50%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic